Clinical Trial Update: A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III trial evaluating NTQ1062 in combination with Fulvestrant for advanced or metastatic hormone receptor-positive/HER2-negative breast cancer is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• NTQ1062

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING